EPSs are serious, debilitating and stigmatizing adverse effects that frequently require additional pharmacotherapy. 3 The two types of EPSs are as follows: early acute EPS, which most often develops ...

Background: Second-generation antipsychotics (SGAs) are thought to have a lower likelihood of inducing extrapyramidal symptoms (EPS) than are first-generation antipsychotics (FGAs). Clinical ...

Oct. 2, 2003 — Olanzapine was associated with the fewest patients with extrapyramidal symptoms (EPS) at six months compared with baseline, according to the results of a large prospective trial ...

Credit: Getty Images. Extrapyramidal symptoms that developed in patients with schizophrenia after initiation of treatment with atypical antipsychotic agents were associated with increased healthcare ...

This study presents a meta-analysis of the influence of several potentially biasing factors (eg industry support, extrapyramidal side effects) on efficacy of studies comparing second-generation ...

New research illuminates the benefits and risks of antipsychotic medication in children and its impact on individual well-being, social, educational and/or vocational functioning, and disease burden.

NEW YORK, Jan. 21, 2021 (GLOBE NEWSWIRE) -- In t ra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

The FDA has notified healthcare professionals that it has updated the Pregnancy section of the labeling for the entire class of antipsychotic drugs. The new drug labeling now provides additional ...

This case highlights vitamin E’s potential as an effective adjunct treatment for patients with antipsychotic-induced motor symptoms resistant to standard therapies. Vitamin E has shown significant ...

Alzheimer’s Death Rate Steadily Increasing; FDA Offers New Guidance Atypical antipsychotics are known to improve many of the symptoms experienced by elderly patients who exhibit neuropsychiatric ...